FAQ on Aditxt Inc.'s Subsidiary Pearsanta's Invitation for DoD-Funded Ovarian Cancer Diagnostic Study
Summary
Aditxt Inc.'s subsidiary, Pearsanta, has been invited to submit a full proposal for a DoD-funded study on its Mitomic Ovarian Test, a novel diagnostic for early ovarian cancer detection, with potential funding of up to $350,000 over two years.
What is the Mitomic Ovarian Test (MOT)?
The Mitomic Ovarian Test (MOT) is a novel blood-based diagnostic developed by Pearsanta, Inc., aimed at early detection of ovarian cancer.
Why is Pearsanta’s invitation to submit a full proposal significant?
This invitation signifies that Pearsanta’s pre-proposal was favorably reviewed for scientific merit and innovation, marking a critical step towards securing funding and advancing the MOT towards clinical validation and commercial launch.
How much funding could Pearsanta receive from the DoD?
If awarded, the grant would provide up to $350,000 over two years to support the validation of the MOT in a multi-center clinical study and prepare for its commercial launch.
What is Aditxt Inc.’s role in this development?
Aditxt Inc. is the parent company of Pearsanta, Inc., providing a social innovation platform that accelerates promising health technologies, including the MOT.
Where can I find more information about Aditxt Inc. and this development?
More information is available in the company’s newsroom at https://ibn.fm/ADTX and on their website at www.Aditxt.com.
What are the next steps for Pearsanta’s MOT?
Pearsanta plans to validate the MOT in a multi-center clinical study and prepare for its commercial launch as a laboratory-developed test, pending the grant award.
How does the MOT compare to existing ovarian cancer diagnostics?
The content does not provide specific comparisons to existing diagnostics, but the MOT is highlighted as a novel blood-based test aimed at early detection, suggesting potential advantages in innovation and scientific merit.
Who is involved in the funding and evaluation of the MOT?
The U.S. Department of Defense’s OCRP Pilot Award is funding the evaluation, with Pearsanta, Inc., a subsidiary of Aditxt Inc., developing the MOT.
When is the MOT expected to be commercially available?
The timeline for commercial availability is not specified, but the grant would support a two-year period for clinical validation and preparation for launch.
What are the potential benefits of the MOT?
The MOT offers the potential for early detection of ovarian cancer through a novel blood-based diagnostic, which could significantly impact patient outcomes by enabling earlier intervention.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 116159